Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Trading Statement

16 Jan 2009 08:31

RNS Number : 7610L
ViaLogy PLC
16 January 2009
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

VIALOGY AND ATASCOSA EXTEND OIL PROJECT; SIGN COMMERCIAL CONTRACT

Friday, January 16, 2009LondonEngland. Vialogy PLC (LSE: VIY) announces today it has signed a contract with Atascosa Exploration LLC to analyze data from three separate oil prospects in south central Texas, known collectively as the Galba Unit. The analysis will determine size and boundaries of reservoirs, overall porosity maps, and optimal well locations. Using its patented QuantumRD™ processing, that exploits subtle variations in geoseismic noise to overcome limitations in current seismic data processing techniques, Vialogy will provide locations for between 6 to 9 wells at sites the companies estimate will be needed to produce the recoverable oil in place

The three prospects include both currently producing areas and new, undeveloped areas. According to Atascosa's geological and engineering estimates, these prospects potentially contain over a million barrels of oil recoverable. ViaLogy's responsibilities include overseeing new, high-resolution 3D seismic surveys, an integrated reservoir assessment, and maintaining reservoir models during the project's life cycle. The first well is planned for completion by Q1 2009. 

This expanded project replaces a previously announced single pilot well, and will accelerate QuantumRD's proof-of-concept across multiple wells in three different formations, achieving one of the company's key business objectives. In addition, the new technology promises to address a problem faced by the oil industry worldwide - drilling dry holes. In Texas itself, 4 out of 10 exploratory wells, including those drilled with the aid of seismic, fail to find gas or oil in economically producible quantities. Such abortive attempts are costly. According to US Dept. of Energy (DOE) Energy Information Administration (EIA) statistics, the 2006 average cost for drilling an on-shore dry hole in the US was over $450,000. 

Under the Atascosa contract, Vialogy will receive for its drill site analysis an interest in production. Atascosa and Vialogy have agreed on 5% of the working interest (WI) back-in after pay-out (BIAPO) to Vialogy in the first well on each prospect. That is, once all well development costs have been paid out, ViaLogy receives 5% of the working interest revenues going forward minus operating expenses. For subsequent wells on each of the three Galba Unit prospects, ViaLogy will receive a right to participate at cost for 5% of the working interest. 

Going forward, the companies have agreed to implement a pricing model for the QuantumRD service based on both a drill site analysis fee and an interest in the prospect. For this contracted project, once drilling is completed, an estimate of the total dollar value of ViaLogy's projected revenues will be possible.

Atascosa CEO, John Mullins, commented, "We have introduced QuantumRD into our critical decision path for determining well location. We believe the unique formation and porosity assessments can deliver revenue growth, and save on production expense. If we prove conclusively that by using the technology we can reduce the number of dry holes, I believe it will have a major impact on the industry." 

Vialogy CEO, Robert W. Dean, said: "We are delighted that Atascosa has decided to extend the use of QuantumRD into a broader exploration and production setting that will best show the capability of this technology, provide revenue, and justify a business model that Vialogy can carry forward."

In anticipation of a successful outcome ViaLogy is making plans to market QuantumRD extensively. 

ViaLogy

Robert W Dean, President & CEO - US (+1 703-589-3807) Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 

Atascosa Exploration LLC John D. Mullins, CEO (+1 210-402-3656) 

Nominated Advisor (Seymour Pierce) Mark Percy +44 (0) 20-7107-8000 

Brokers to ViaLogy PLC 

St. Helen's Capital +44 (0) 7628 5582

About ViaLogy: Network Centric Signal Processing ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTGUUUWGUPBURQ
Date   Source Headline
5th Nov 20207:00 amRNSDirectorate Change
3rd Nov 20207:00 amRNSPartnership with Take2 Health Limited
26th Oct 20207:00 amRNSHalf-year Trading update
23rd Oct 20207:00 amRNSCQC accreditation
21st Oct 20207:00 amRNSYourgene Genomic Services collaboration with Cytox
12th Oct 20207:00 amRNSElucigene DPYD tests to be used routinely in Wales
8th Oct 20207:00 amRNSStrategic reproductive health partnership in Japan
7th Oct 20207:00 amRNSIONA®Nx awarded contract with St George’s Hospital
5th Oct 20207:00 amRNSShare Incentive Plan
1st Oct 20204:59 pmRNSCorrection: Holding(s) in Company
1st Oct 20203:29 pmRNSHolding(s) in Company
28th Sep 20207:00 amRNSLaunch of Yourgene Genomic Services
25th Sep 20205:28 pmRNSIssue of Share Options
24th Sep 202010:00 amRNSDPD reimbursement in Germany
24th Sep 20207:00 amRNSDirector/PDMR Shareholding
23rd Sep 20205:20 pmRNSExercise of Options
23rd Sep 202012:25 pmRNSDirector/PDMR Shareholding
22nd Sep 20205:14 pmRNSResult of AGM
22nd Sep 20207:00 amRNSAGM Statement
21st Sep 20207:00 amRNSUS distribution agreement for DPYD &other products
9th Sep 20207:00 amRNSAGM update and investor presentation
3rd Sep 20207:00 amRNSIONA® Nx Launch
28th Aug 20207:00 amRNSNotice of AGM & Annual Report 2020
13th Aug 20207:00 amRNSTGA approves IONA® Nx for sale in Australia
11th Aug 20207:00 amRNSAdmission of Company Considerations Shares and TVR
7th Aug 20203:42 pmRNSHolding(s) in Company
7th Aug 20203:25 pmRNSHolding(s) in Company
7th Aug 20209:48 amRNSHolding(s) in Company
5th Aug 20201:15 pmRNSResult of Placing
5th Aug 20207:00 amRNS£16.15m Placing & Close of Accelerated Bookbuild
4th Aug 20205:13 pmRNSProposed Acquisition and Placing
3rd Aug 20207:00 amRNSCE-IVD Mark for Clarigene™ SARS-CoV-2 test
29th Jul 202012:05 pmRNSAppointment of Joint Broker
28th Jul 20207:00 amRNSFinal Results
13th Jul 20201:13 pmRNSNotice of Results
30th Jun 20207:00 amRNSCOVID-19 assay launched
19th Jun 20204:44 pmRNSIssue of Share Options
16th Jun 20207:00 amRNSCollaboration in COVID-19 testing
15th Jun 20207:00 amRNSCE-IVD mark received for Illumina-based IONA® test
26th May 202012:00 pmRNSHolding(s) in Company
26th May 20207:00 amRNSCOVID-19 testing service launch; business update
20th May 20207:00 amRNSExercise of Warrants and Options
20th Apr 20207:00 amRNSYear-end Trading update: Revenues increase 86%
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:36 pmRNSPrice Monitoring Extension
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSPresentation on ‘Adapting during crisis’

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.